Lynas Rare Earths Shares Rise After Takeover Talks Revealed 
Amazon Shares Fall as FTC Plans Ad Pricing Lawsuit 
Trump Secures Drug Pricing Deals With Nine Pharma Companies 
Berkshire Hathaway Eyes Bigger Stakes in Japan’s Top Trading Houses 
Deutsche Telekom Shares Rise as Elliott Pushes Against T-Mobile Merger 
Thomson Reuters C-Track Cyberattack Hits Courts Across U.S. and Canada 
CATL Shares Fall as Hungary Plant Faces Safety Halt 
Shein Shares Slide 9% in Hong Kong IPO Debut 
BP Names Ian Tyler Permanent Chairman After Governance Shake-Up 
Trump Says ExxonMobil Among Oil Majors Planning Venezuela Return 
Shein Shares Drop 5% After Weak Hong Kong IPO Debut 
Microsoft to Reveal Azure Revenue in Major Reporting Shake-Up 
Lenovo Shares Fall After Dropbox Security Breach Exposes ID Vulnerability 
ByteDance Secures $29.6 Billion Loan to Boost AI Investment 
Audi, SAIC Launch China Innovation Hub for New AUDI Models 
Honda Targets $9.4 Billion in Cost Cuts as China EV Competition Intensifies 
OpenAI Nears Astra AI Model Launch With Safety Focus 
Add as a preferred source on Google
NEW YORK, March 13, 2018 --
Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced management will be participating in the following investor conference:
- Oppenheimer 28th Annual Healthcare Conference on March 19, 2018 at 10:20 a.m. Eastern Time
Webcast information for this event will be available on the Investors page of Intercept's website at http://ir.interceptpharma.com. Archived webcasts will be available on Intercept's website for approximately two weeks.
About Intercept
Intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, including primary biliary cholangitis (PBC), nonalcoholic steatohepatitis (NASH), primary sclerosing cholangitis (PSC) and biliary atresia. Founded in 2002 in New York, Intercept now has operations in the United States, Europe and Canada.
CONTACT: For more information about
Intercept Pharmaceuticals, please contact:
Intercept Pharmaceuticals:
Mark Vignola
+1-646-747-1000
[email protected]
Media inquiries: [email protected]
Investor inquiries: [email protected]
